Back to search results

Study of STP938 (Dencatistat) for Advanced Solid Tumors

This study is testing a drug called STP938 (Dencatistat) in people with advanced solid tumors (cancers that form in solid organs like the breast or lung). The main goal is to see how safe STP938 is and if people can tolerate it, over an average of 6 months. You might be able to join if you are at least 18 years old, have advanced cancer that can't be cured by other treatments, and have tumor tissue available for testing. This study is currently recruiting participants.

Study design
This is an interventional study with a planned enrollment of 70 participants. It involves two parts: a dose escalation (Phase 1a) and a safety expansion (Phase 1b) of STP938 as a single treatment.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Safety and tolerability will be measured through study completion, an average of 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06297525

Study of STP938 (Dencatistat) in Advanced Solid Tumours

Recruiting
PHASE1Ages 18+InterventionalTreatment
Step Pharma, SAS
~70 participants
Updated 2026-06-16 on ClinicalTrials.gov
What's tested:STP938

At a glance

Recruiting sites
7 of 7 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and Tolerability
Measured over Through study completion, an average of 6 months

Conditions

Solid Tumor

Explore related trials

Solid Neoplasm

NCT06297525

Where you'd take part

This study runs at 7 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Comprehensive Hematology Oncology, LLC

    St. Petersburg, Floridano site contact published

    Recruiting

  • Institut Gustave Roussy

    Villejuif, Paris, Franceno site contact published

    Recruiting

  • Mary Crowley Cancer Research Center

    Dallas, Texasno site contact published

    Recruiting

  • Next Oncology

    San Antonio, Texasno site contact published

    Recruiting

  • The Beatson Institute for Cancer Research

    Glasgow, Glasgow, United Kingdomno site contact published

    Recruiting

  • The Christie

    Manchester, United Kingdomno site contact published

    Recruiting

  • University College London

    London, United Kingdomno site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Maureen Higgins · STUDY_DIRECTOR · Step Pharma

Who to contact

Maureen Higgins
[email protected]
+33 1 86 26 43 56
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Signed and dated informed consent, and able to comply with the study procedures and any locally required authorization.
Male or female aged ≥ 18 years.
Advanced disease not curable by available therapies and requires systemic therapy.
Histologically confirmed diagnosis of eligible cancer type.
Must have tumor tissue available for biomarker testing.
Measurable disease (Part 1) and measurable disease per RECIST (Part2)
Eastern Cooperative Oncology Group (ECOG) performance status ≤2.
Life expectancy \> 3 months as assessed by the Investigator.
Adequate organ function (bone marrow, hepatic, renal function and coagulation).
All toxicities (except alopecia) from prior cancer treatments or procedures must have resolved to ≤Grade 1 or returned to baseline levels prior to enrollment.

Exclusion

Pregnant or breastfeeding females and women of childbearing potential or males unwilling to comply with contraception requirements.
Known active or symptomatic CNS metastases, carcinomatous meningitis, leptomeningeal disease or a history of spinal cord compression
Active malignancy within 2 years of study enrollment
Prior radiation within 2 weeks of start of therapy.
Systemic cancer treatments, monoclonal antibody-directed therapies, other investigational agents within 4 weeks before enrollment, or \<5 half-lives since completion of previous investigational therapy, whichever is shorter.
Uncontrolled intercurrent illness.
Immunocompromised subjects with increased risk of opportunistic infections or history of opportunistic infection in the last 12 months.
Known active or chronic hepatitis B or active hepatitis C virus (HCV) infection.
Subjects with corrected QT interval \>470 msec based on averaged triplicate electrocardiogram (ECG) readings at the Screening Visit using the QT interval corrected for heart rate using Fridericia's method (QTcF).

What this trial measures

  • Safety and TolerabilityThrough study completion, an average of 6 months

    Incidence of dose limiting toxicities (DLTs), serious adverse events (SAEs), treatment-emergent adverse events (TEAEs)